Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents
Ramadan, H., Nagiub, E., Eltyb, H., Mohammed, M. (2021). Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents. EKB Journal Management System, 5(2), 49-55. doi: 10.21608/jcbr.2021.44109.1072
Haidi K. Ramadan; Eman M. Nagiub; Hanan A. Eltyb; Mahmoud Mohammed. "Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents". EKB Journal Management System, 5, 2, 2021, 49-55. doi: 10.21608/jcbr.2021.44109.1072
Ramadan, H., Nagiub, E., Eltyb, H., Mohammed, M. (2021). 'Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents', EKB Journal Management System, 5(2), pp. 49-55. doi: 10.21608/jcbr.2021.44109.1072
Ramadan, H., Nagiub, E., Eltyb, H., Mohammed, M. Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents. EKB Journal Management System, 2021; 5(2): 49-55. doi: 10.21608/jcbr.2021.44109.1072

Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents

Egyptian Journal of Cancer and Biomedical Research
Article 5, Volume 5, Issue 2, June 2021, Page 49-55  XML PDF (1.5 MB)
Document Type: Letter to the Editor
DOI: 10.21608/jcbr.2021.44109.1072
View on SCiNiTO View on SCiNiTO
Authors
Haidi K. Ramadanorcid 1; Eman M. Nagiuborcid 2; Hanan A. Eltyborcid 3; Mahmoud Mohammed email orcid 4
1Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.
2Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
3Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
4Surgical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Abstract
Background: The Red cell distribution width (RDW) shows a significant increase both in the hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC). Treatment of HCV has changed following the introduction of direct-acting antivirals (DAAs) with a higher sustained virological response rate (SVR). However, HCC is still developed after DAAs therapy. Aim: The study aimed to assess the changes of RDW in HCC patients with HCV viremia and after SVR12 to DAAs. Methods: This work is based on a retrospective cohort study including 120 patients allocated into 3 groups, 40 / each. Group 1: patients with HCV-related liver cirrhosis without HCC and not treated with DAAs, group 2: patients with liver cirrhosis and HCC without DAAs and group 3: patients with liver cirrhosis and developed HCC following SVR12 to DAAs. Liver profile, International Normalized Ratio (INR) and creatinine indices were measured with an assessment of Child class CBC for measurement of RDW and RDW/Platelet ratio (RPR) were done. Results: The red distribution width (RDW) was mildly elevated in group 3 compared to group 2. The ratio of RDW/Platelet was almost similar in group 2 and group 3. RDW increased in group 3 relative to group 2 in all Child classes with a significantly higher level in Child A and B. Conclusion: Clearance of HCV following DAAs did not have a major impact on RDW in HCC patients after DAAs therapy which is not different from viremic patients with HCC.
Keywords
Red cell distribution width; Red cell distribution width/platelet ratio; Direct Acting-Antivirals; Hepatitis C virus
Statistics
Article View: 383
PDF Download: 363